Elad Sharon

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Elad Sharon
Oct 4, 2024, 09:33 | Blog
Elad Sharon meet Estela Rodriguez at Evolving Therapies meeting
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, posted on X: "I got to meet…
Oct 2, 2024, 14:22 | Blog
Elad Sharon: Kimryn Rathmell addresses the dinner for the annual meeting of the CEO Round Table on Cancer
Elad Sharon, Medical Oncologist, Dana-Farber Cancer Center, shared a post on X: "⁦Dr. Kimryn Rathmell addresses…
Oct 1, 2024, 14:53 | Blog
Elad Sharon: The immune system is almost always involved with cancer
Elad Sharon, Medical Oncologist at Dana-Farber, shared his recent article on X: "The immune system is…
Oct 1, 2024, 13:56 | Blog,Opinion
Elad Sharon: Evolving Therapeutics Symposium 2024
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Center, shared on X: ''We got a nice…
Sep 30, 2024, 15:56 | Blog
Elad Sharon: New framework to consider phase 1 clinical trials ⁦
Elad Sharon, Medical Oncologist at Dana-Farber, shared on X:   "Nagla Abdel Karim gives us a new…
Sep 24, 2024, 12:30 | Societies
11 ESMO24 presentations published on NEJM
At the 2024 ESMO Congress, 11 articles were presented that were published in NEJM, highlighting…
Aug 29, 2024, 17:01 | Insight
Elad Sharon: Quite promising for c-MET over-expressing NSCLC
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Giuseppe Banna, Consultant…
Aug 28, 2024, 13:52 | Insight
Article of the day, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 19, 2024, 08:17 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 14, 2024, 15:35 | Blog
Elad Sharon: So much we can do together to reduce the burden and suffering from cancer
Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared a post by Danielle…
Aug 10, 2024, 03:56 | Insight
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia
Bichoy Gabra, Oncology Infusion Pharmacy Services Manager at Moffitt Cancer Center, shared on X: "Many…
Aug 4, 2024, 06:32 | Insight
Elad Sharon: One of my favorite recent efforts from the SWOG Cancer Research Network's DART trial - a look at linear change in tumor size
Elad Sharon, Clinical and Translational Director at Dana-Farber Cancer Institute, shared JNCI's (Journal of the…
Aug 2, 2024, 11:14 | Insight
Razelle Kurzrock: Our newest DART study
Razelle Kurzrock shared a post by the Journal for ImmunoTherapy of Cancer on X, adding:…
Aug 2, 2024, 02:11 | Insight
Razelle Kurzrock: Our newest DART study
Razelle Kurzrock shared a post by Journal for ImmunoTherapy of Cancer, on X, adding: "Our…
Jul 28, 2024, 14:38 | Drugs
Elad Sharon: Contribution of effect is an under appreciated and essential part of drug development
Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared a post by FDA Oncology…
Jul 25, 2024, 21:25 | Blog
Elad Sharon: Another win for patients with ALL
Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared on X: "Another win for…
Jul 25, 2024, 21:01 | Blog
Caner Saygin: A testament to the fact that flow MRD is insufficient for making treatment decisions in ALL
Caner Saygin, Assistant Professor of Medicine at University of Chicago, shared a post by NEJM, on X:…
Jul 9, 2024, 07:25 | Insight
Piotr Wysocki: Checkpoint inhibitor and TKI combinations in GU malignancies
Piotr Wysocki recently posted on LinkedIn: "A phase I study (Apolo AB et al. J Clin…
Jun 29, 2024, 10:28 | Societies
The perfect is the enemy of the good
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared on X: "“The perfect is the…
Jun 21, 2024, 11:57 | Blog
Elad Sharon: Two of my major trials led to FDA Oncology approvals
Elad Sharon, Clinical and Translational Director of Dana-Farber Cancer Institute, shared on X/Twitter: "Past week,…
Apr 14, 2024, 10:33 | Opinion
Elad Sharon: Designing clinical trials is all about tradeoffs
Elad Sharon, Clinical and Translational Director of Immunotherapy Toxicity Service at Dana-Farber Cancer Institute, shared…
Apr 8, 2024, 11:46 | Blog
Elad Sharon: Listening to my mentee, Rafeh Naqash, present some incredible data at the ⁦SWOG plenary!
Elad Sharon, Clinical and Translational Director at Dana-Farber Cancer Institute, shared a post on X: "Listening to…
Mar 27, 2024, 14:24 | Blog
Elad Sharon: A great honor to speak at The Tisch Cancer Institute this week at Hematology Oncology Grand Rounds
Elad Sharon, Clinical and Translational Director at Dana-Farber Cancer Institute, shared a post by The Tisch Cancer Institute,…
Feb 23, 2024, 17:26 | Blog
Elad Sharon: Honored to receive a plaque for our team’s work getting the first immune checkpoint inhibitor approved in sarcoma!
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, made the following post on X: "Honored…
Jan 31, 2024, 14:14 | Blog
Elad Sharon: The hottest new ICI BOTENSILIMAB in Kidney Cancer
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Michael Serzan, Genitourinary…
Jan 23, 2024, 10:44 | Insight
Joanna Baginska: The results for a melanoma expansion cohort of a phase 1B, multicenter, open-label study
Joanna Baginska, Lead Scientist at Dana-Farber Cancer Institute, shared a post on LinkedIn: "In this…
Dec 28, 2023, 17:21 | Blog
Rafeh Naqash: Honor of a lifetime
Quoting Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Centre, on X/Twitter: “Honor of…
Sep 10, 2023, 23:05 | Blog
Elad Sharon: I am ecstatic to announce that I am joining Dana-Farber as the Clinical and Translational Director of the iTOX Service.
Quoting Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, on X/Twitter: ''I am ecstatic to announce…
All: 28 Posts: 1 - 100
Special Coverage